HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Custodiol-N solution

a chloride- and histidine-poor cardioplegic solution based on Custodiol and supplemented by cytoprotective amino acids

Also Known As:

Custodiol-N

Networked: 8 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Pharmaceutical Preparations
- Solutions: 41770
  - Organ Preservation Solutions: 23
    - Custodiol-N solution: 8

Experts

1.	Karck, Matthias: 3 articles (10/2022 - 04/2010)
2.	Szabó, Gábor: 3 articles (10/2022 - 04/2010)
3.	Loganathan, Sivakkanan: 2 articles (10/2022 - 04/2010)
4.	Veres, Gábor: 2 articles (10/2022 - 02/2015)
5.	Schemmer, Peter: 2 articles (10/2020 - 01/2020)
6.	Stiegler, Philipp: 2 articles (10/2020 - 01/2020)
7.	Dieterlen, Maja-Theresa: 2 articles (01/2020 - 01/2019)
8.	Hoyer, Alexandro: 2 articles (01/2020 - 01/2019)
9.	Klaeske, Kristin: 2 articles (01/2020 - 01/2019)
10.	Radovits, Tamás: 2 articles (02/2015 - 04/2010)

Related Diseases

1.	Reperfusion Injury 10/04/2022 - "Significantly reduced peak CK-MB levels in the Custodiol-N group in the full analysis set may implicate a beneficial effect on ischaemia/reperfusion injury in the setting of coronary bypass surgery." 02/28/2015 - "The observed protective effects imply that the Custodiol-N could be the next generation cardioplegic solution in the protection against ischemia-reperfusion injury in cardiac surgery." 04/01/2010 - "Effects of Custodiol-N, a novel organ preservation solution, on ischemia/reperfusion injury." 02/28/2015 - "Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass."
2.	Heart Arrest (Cardiac Arrest) 02/28/2015 - "The use of Custodiol-N cardioplegic solution improved coronary blood flow (58 ± 7 ml/min vs. 26 ± 3 ml/min) and effectively prevented cardiac dysfunction after cardiac arrest. " 02/01/2009 - "Rat livers were harvested 30 min after cardiac arrest, flushed via the portal vein and cold-stored in HTK or modified HTK-solution (Custodiol-N) for 18 h at 4 degrees C. " 02/28/2015 - "The new HTK cardioplegic solution (Custodiol-N) improved myocardial and endothelial function after cardiopulmonary bypass with hypothermic cardiac arrest. "
3.	Cold Injury 01/10/2020 - "Preclinical data have clearly shown that Custodiol-N is superior to Custodiol® in cold static organ preservation via mechanisms including inhibition of hypoxic cell injury, cold-induced cell injury and avoidance of adverse effects during warm exposure to the solution. "
4.	Edema (Dropsy) 10/28/2020 - "This study demonstrated that Custodiol-N protects uterus grafts from cold ischemic injury better than standard Custodiol® most likely via inhibition of oxidative stress and tissue edema. " 10/28/2020 - "After 8 h of cold ischemia, higher percentage of tissue edema, necrosis signs and myeloperoxidase expression, as well as lower superoxide dismutase activity were found in Custodiol® compared to Custodiol-N (p < 0.05). "
5.	Acute Kidney Injury (Acute Renal Failure) 01/01/2020 - "Impact of Custodiol-N cardioplegia on acute kidney injury after cardiopulmonary bypass."

Related Drugs and Biologics

1.	Solutions
2.	Cardioplegic Solutions
3.	Superoxide Dismutase
4.	Peroxidase (Myeloperoxidase)
5.	Bretschneider cardioplegic solution

Related Therapies and Procedures

1.	Cardiopulmonary Bypass (Heart-Lung Bypass)
2.	Induced Heart Arrest (Cardioplegia)